|
Encephalomyelitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Through a combination of proteomic, metabolomic, transcriptomic, and perturbation studies, we found that sphingolipid metabolism in astrocytes triggers the interaction of the C2 domain in cytosolic phospholipase A2 (cPLA2) with the CARD domain in mitochondrial antiviral signaling protein (MAVS), boosting NF-κB-driven transcriptional programs that promote CNS inflammation in experimental autoimmune encephalomyelitis (EAE) and, potentially, multiple sclerosis. cPLA2 recruitment to MAVS also disrupts MAVS-hexokinase 2 (HK2) interactions, decreasing HK enzymatic activity and the production of lactate involved in the metabolic support of neurons.
|
31813625 |
2019 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Through a combination of proteomic, metabolomic, transcriptomic, and perturbation studies, we found that sphingolipid metabolism in astrocytes triggers the interaction of the C2 domain in cytosolic phospholipase A2 (cPLA2) with the CARD domain in mitochondrial antiviral signaling protein (MAVS), boosting NF-κB-driven transcriptional programs that promote CNS inflammation in experimental autoimmune encephalomyelitis (EAE) and, potentially, multiple sclerosis. cPLA2 recruitment to MAVS also disrupts MAVS-hexokinase 2 (HK2) interactions, decreasing HK enzymatic activity and the production of lactate involved in the metabolic support of neurons.
|
31813625 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Higher PLA2G4A expression is associated with mutations in NRAS (P < .001), RUNX1 (P = .012), ASXL1 (P = .007), and EZH2 (P = .038), all of which are known to contribute to MDS development.
|
31738830 |
2019 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data support the hypothesis that glutamate signals cPLA2 activation, resulting in overexpression of blood-brain barrier P-gp and BCRP.-Hartz, A. M. S., Rempe, R. G., Soldner, E. L. B., Pekcec, A., Schlichtiger, J., Kryscio, R., Bauer, B. Cytosolic phospholipase A2 is a key regulator of blood-brain barrier function in epilepsy.
|
31661303 |
2019 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Based on our previous studies, we hypothesized that glutamate released during seizures activates cytosolic phospholipase A2 (cPLA2), resulting in P-gp and BCRP overexpression.
|
31661303 |
2019 |
|
Status Epilepticus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We also demonstrated, <i>in vivo</i>, that cPLA2 inhibition prevents overexpression of P-gp and BCRP at the blood-brain barrier in rats after status epilepticus and in CE rats.
|
31661303 |
2019 |
|
Aqueous Humor Disorders
|
0.020 |
Biomarker
|
disease |
BEFREE |
Although autotaxin, a secreted lysophospholipase D and its catalytic product lysophosphatidic acid (LPA) have been shown to modulate AH drainage through TM, we do not have a complete understanding of their role and regulation in glaucoma patients, TM and AH outflow.
|
31648019 |
2020 |
|
Glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although autotaxin, a secreted lysophospholipase D and its catalytic product lysophosphatidic acid (LPA) have been shown to modulate AH drainage through TM, we do not have a complete understanding of their role and regulation in glaucoma patients, TM and AH outflow.
|
31648019 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cytosolic phospholipase A2 α (cPLA2α), along with downstream proinflammatory and promigratory metabolites, has been implicated in several aspects of tumorigenesis, as well as metastasis, in various types of cancer.
|
31569627 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Cytosolic phospholipase A2 α (cPLA2α), along with downstream proinflammatory and promigratory metabolites, has been implicated in several aspects of tumorigenesis, as well as metastasis, in various types of cancer.
|
31569627 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Cytosolic phospholipase A2 α (cPLA2α), along with downstream proinflammatory and promigratory metabolites, has been implicated in several aspects of tumorigenesis, as well as metastasis, in various types of cancer.
|
31569627 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Cytosolic phospholipase A2 α (cPLA2α), along with downstream proinflammatory and promigratory metabolites, has been implicated in several aspects of tumorigenesis, as well as metastasis, in various types of cancer.
|
31569627 |
2019 |
|
Enzyme inhibition disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, we argue that cPLA2α is a potential therapeutic target in cancer and that enzyme inhibition may inhibit metastasis through an anti-migratory mechanism, possibly involving Toll-like receptor signaling and type I interferons.
|
31569627 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our study indicated that cPLA2α may promote cell-matrix adhesion <i>via</i> the FAK/paxillin pathway, which partly explains the malignant cPLA2α phenotype seen in HCC.
|
31516757 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The effect of PLA2G4A downstream signaling, including Cyclooxygenase 2, Prostaglandin E2(PGE2) and Signal transducer and activator of transcription 3(STAT3), on EMT and metastasis was further detected with in vitro and in vivo experiments.
|
31492557 |
2019 |
|
Congenital contractural arachnodactyly
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we screened the key molecule in ANXA10-induced CCA progression by mRNA sequencing and evaluated the correlation between PLA2G4A and ANXA10.
|
31492557 |
2019 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, with the protection of acetone against tissue antigenicity, we successfully characterized the expression of three metabolites-related enzymes, fatty acid synthase (FASN), glutaminase (GLS), and cytosolic phospholipase A2 (cPLA2) in osteosarcoma.
|
31404800 |
2019 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, with the protection of acetone against tissue antigenicity, we successfully characterized the expression of three metabolites-related enzymes, fatty acid synthase (FASN), glutaminase (GLS), and cytosolic phospholipase A2 (cPLA2) in osteosarcoma.
|
31404800 |
2019 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, with the protection of acetone against tissue antigenicity, we successfully characterized the expression of three metabolites-related enzymes, fatty acid synthase (FASN), glutaminase (GLS), and cytosolic phospholipase A2 (cPLA2) in osteosarcoma.
|
31404800 |
2019 |
|
Malignant neoplasm of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
|
31347609 |
2019 |
|
Carcinoma of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
|
31347609 |
2019 |
|
Primary malignant neoplasm of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
|
31347609 |
2019 |
|
Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Fexofenadine potently inhibited TNF/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB) signalling in vitro and in vivo, and ameliorated disease symptoms in inflammatory arthritis models. cPLA2 was isolated as a novel target of fexofenadine.
|
31302596 |
2019 |
|
Neurodegenerative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Together, our data indicate that PLA2G4A -mediated lysosomal membrane damage is involved in neuronal cell death following CCI-induced TBI and potentially in other neurodegenerative disorders.
|
31238788 |
2020 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The plasma concentration of iPLA2 in patients with schizophrenia was significantly higher than that in healthy controls while the plasma concentration of cPLA2 did not differ.
|
31207866 |
2019 |